HC Wainwright Reaffirms Neutral Rating for BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical (NASDAQ:BMRN)‘s stock had its “neutral” rating reaffirmed by investment analysts at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They currently have a $60.00 target price on the biotechnology company’s stock. HC Wainwright‘s price target would suggest a potential upside of 8.97% from the company’s current price.

A number of other research firms have also recently commented on BMRN. Barclays increased their target price on BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 14th. UBS Group initiated coverage on BioMarin Pharmaceutical in a research report on Thursday, October 15th. They issued a “buy” rating and a $88.00 price target for the company. Piper Sandler upped their price target on shares of BioMarin Pharmaceutical from $88.00 to $90.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 1st. Stifel Nicolaus dropped their price target on shares of BioMarin Pharmaceutical from $70.00 to $66.00 and set a “hold” rating on the stock in a research note on Tuesday. Finally, BMO Capital Markets reissued an “outperform” rating on shares of BioMarin Pharmaceutical in a research report on Wednesday, September 16th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $88.09.

BioMarin Pharmaceutical Stock Down 4.1%

Shares of BMRN traded down $2.38 during mid-day trading on Tuesday, reaching $55.06. The company had a trading volume of 1,499,676 shares, compared to its average volume of 2,110,063. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39. The firm has a 50-day moving average price of $60.43 and a 200 day moving average price of $58.46. BioMarin Pharmaceutical has a 52 week low of $49.26 and a 52 week high of $70.98. The company has a market capitalization of $10.66 billion, a price-to-earnings ratio of 148.64, a price-to-earnings-growth ratio of 0.61 and a beta of 0.22.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings data on Monday, November 2nd. The biotechnology company reported $0.23 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.31. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.02 billion. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%. The firm’s revenue for the quarter was up 32.0% on a year-over-year basis. During the same quarter last year, the company earned $0.12 EPS. On average, sell-side analysts forecast that BioMarin Pharmaceutical will post 2.59 EPS for the current year.

Institutional Trading of BioMarin Pharmaceutical

Several institutional investors have recently added to or reduced their stakes in BMRN. Kestra Advisory Services LLC raised its stake in shares of BioMarin Pharmaceutical by 23.4% in the third quarter. Kestra Advisory Services LLC now owns 4,520 shares of the biotechnology company’s stock worth $271,000 after purchasing an additional 857 shares during the last quarter. Bfsg LLC bought a new position in shares of BioMarin Pharmaceutical during the third quarter valued at $1,052,000. Oregon Public Employees Retirement Fund lifted its holdings in shares of BioMarin Pharmaceutical by 0.5% during the third quarter. Oregon Public Employees Retirement Fund now owns 40,117 shares of the biotechnology company’s stock valued at $2,407,000 after purchasing an additional 200 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in shares of BioMarin Pharmaceutical during the third quarter valued at $186,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of BioMarin Pharmaceutical during the third quarter valued at $705,000. 98.71% of the stock is currently owned by hedge funds and other institutional investors.

Key BioMarin Pharmaceutical News

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin reported third-quarter revenue of $1.025 billion, up 32% year over year and in line with expectations. Adjusted EPS was $0.23, well above the consensus estimate for a loss of roughly $0.08–$0.09. Growth was led by a 44% increase in metabolic-condition revenue and a 12% rise in skeletal-condition revenue. BioMarin Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: The company added a new investigational Fabry disease asset to its clinical portfolio and reported a May 30, 2027 PDUFA action date for VOXZOGO in hypochondroplasia, supporting BioMarin’s longer-term growth story.
• Positive Sentiment: Options activity was notably bullish, with traders purchasing 3,961 call options—about 228% above typical call volume—suggesting increased speculative interest in a potential rebound.
• Neutral Sentiment: Analyst opinion remains mixed. Citi reiterated a Buy rating, while Royal Bank of Canada maintained a Sector Perform rating, indicating that near-term execution concerns are balanced against BioMarin’s pipeline potential.
• Negative Sentiment: BioMarin lowered its 2026 adjusted EPS guidance to $2.80–$3.10, below the $3.32 analyst consensus, and issued revenue guidance of $3.8 billion–$3.9 billion versus the $3.9 billion consensus. Management cited order-timing uncertainty and charges related to two acquired in-process research programs. BioMarin Q3 2026 Results and Guidance
• Negative Sentiment: Royal Bank of Canada lowered its BMRN price target from $62 to $60 while retaining its Sector Perform rating, reinforcing investor concerns about limited near-term upside.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.